María Díez Campelo, MD, PhD, is a hematologist at the University Hospital of Salamanca.
Evaluating Imetelstat's Impact on Health-Related Quality of Life in Lower-Risk MDS: María Díez Campelo, MD, PhD
The phase 3 IMerge trial (NCT02598661) evaluated how treatment with imetelstat impacts health-related quality of life in patients with lower-risk myelodysplastic syndromes (MDS), according to María Díez Campelo, MD, PhD.